These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7653449)

  • 21. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
    Morris S
    Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
    Iakoubova OA; Tong CH; Rowland CM; Kirchgessner TG; Young BA; Arellano AR; Shiffman D; Sabatine MS; Campos H; Packard CJ; Pfeffer MA; White TJ; Braunwald E; Shepherd J; Devlin JJ; Sacks FM
    J Am Coll Cardiol; 2008 Jan; 51(4):435-43. PubMed ID: 18222353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease.
    Ford I; Shah AS; Zhang R; McAllister DA; Strachan FE; Caslake M; Newby DE; Packard CJ; Mills NL
    J Am Coll Cardiol; 2016 Dec; 68(25):2719-2728. PubMed ID: 28007133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 33. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris.
    Am J Cardiol; 1995 Sep; 76(7):474-9. PubMed ID: 7653447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
    J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
    Freeman DJ; Norrie J; Sattar N; Neely RD; Cobbe SM; Ford I; Isles C; Lorimer AR; Macfarlane PW; McKillop JH; Packard CJ; Shepherd J; Gaw A
    Circulation; 2001 Jan; 103(3):357-62. PubMed ID: 11157685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).
    Sacks FM; Pfeffer MA; Moye' L; Brown LE; Hamm P; Cole TG; Hawkins CM; Braunwald E
    Am J Cardiol; 1991 Dec; 68(15):1436-46. PubMed ID: 1746424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
    Byington RP; Davis BR; Plehn JF; White HD; Baker J; Cobbe SM; Shepherd J
    Circulation; 2001 Jan; 103(3):387-92. PubMed ID: 11157690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
    Iakoubova OA; Tong CH; Chokkalingam AP; Rowland CM; Kirchgessner TG; Louie JZ; Ploughman LM; Sabatine MS; Campos H; Catanese JJ; Leong DU; Young BA; Lew D; Tsuchihashi Z; Luke MM; Packard CJ; Zerba KE; Shaw PM; Shepherd J; Devlin JJ; Sacks FM
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2763-8. PubMed ID: 17008591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.